Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Instil Bio, Inc. (NQ:TIL)

34.23 -3.28 (-8.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Instil Bio, Inc.

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
These stocks are moving in today's after hours session
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
These stocks that are showing activity before the opening bell on Monday.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Keep an eye on the top gainers and losers in Thursday's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
These stocks are moving in today's session
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2023. 
Via InvestorPlace
What's going on in today's pre-market session
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
These relatively small companies are developing new cancer therapies that could generate billions in annual sales. 
Via The Motley Fool
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. 
Via The Motley Fool
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Via Benzinga
Exposures Fossil Fuels
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy. 
Via The Motley Fool
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,... 
Via Talk Markets
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday 
Via InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.